Table 2. Selected ongoing combination clinical trials with a PARP inhibitor.
| Tumor type/eligibility | Experimental Combination | Randomized | Phase | NCT number |
|---|---|---|---|---|
| Solid tumors (metastatic)1 | olaparib and AZD5363 | No | Phase I | NCT02338622 |
| Triple (-) Breast cancer or Ovarian cancer | olaparib+BKM120 or BLY719 | No | Phase I | NCT01623349 |
| Ewing's sarcoma (previously treated) | niraparib+temozolomide | No | Phase I | NCT02044120 |
| Breast cancer (inoperable/inflammatory/metastatic) | Olaparib+radiotherapy | No | Phase I | NCT02227082 |
| Triple (-) Breast cancer or Ovarian cancer2 | Olaparib+mTORC1/2i or AZD5363 (AKTi)3 | No | Phase Ib | NCT02208375 |
| Triple (-) Breast Cancer or Ovarian Cancer | cediranib+olaparib vs olaparib | Yes | Phase I/II | NCT0116648 |
| Non-small cell lung cancer (stage III) | Veliparib+paclitaxel/carbo (VPC) +XRT followed by VPC consolidation | Yes | Phase I/II | NCT02412371 |
| Refractory solid tumors4 (Phase II: Ewing's and ALL) | BMN 673 (talazoparib)+/-temozolomide | No | Phase I/II | NCT02116777 |
| Small Cell lung cancer | Veliparib+carboplatin/etoposide | Yes | Phase I/II | NCT02289690 |
| Advanced Solid tumors | NCI-MPACT5 veliparib + temozolomide |
Yes | Phase II | NCT01827384 |
| Glioblastoma Multiforme (newly diagnosed) | Temozolamide+/-veliparib6 | Yes | Phase II/III | NCT02152982 |
| Breast cancer (HER2neg or gBRCAm) | Carboplatin+paclitaxel with veliparib or placebo | Yes | Phase III | NCT02163694 |